drugset / Trial / NCT07284290
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
Phase 4
Recruiting
120 enrolled
Virginia Commonwealth University
National Institute of Neurological Disorders and Stroke (NINDS) · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan
Timeline
- Start
- 2025-12-08
- Primary completion
- 2029-11
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Galantamine | Small molecule | 16 mg | — |